33 Results

People

  1. Palomba
    Palomba
  2. Zelenetz
    Zelenetz
  3. Hamlin
    Hamlin
  4. Horwitz
    Horwitz
  5. Intlekofer
    Intlekofer
  6. Noy
    Noy
  7. Moskowitz
    Moskowitz
  8. Kumar
    Kumar
  9. Caron
    Caron
  10. Batlevi
    Batlevi

Groups

  1. Center for Hematologic Malignancies (33)
  2. Department of Medicine (33)
  3. GSK Faculty (33)
  4. Hematologic Malignancies Research (33)
  5. Hematologic Malignancies, Division of (33)
  6. Lymphoma (33)
  7. Population Sciences Research Program (33)
  8. Human Oncology and Pathogenesis Program (27)
  9. Survivorship Research (24)
  10. Sloan Kettering Institute Postdocs (23)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Population Sciences Research Program"
  4. "Maria Palomba"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (5)
Groups
  1. Center for Hematologic Malignancies (33)
  2. Department of Medicine (33)
  3. GSK Faculty (33)
  4. Hematologic Malignancies Research (33)
  5. Hematologic Malignancies, Division of (33)
  6. Lymphoma (33)

More Groups

People
  1. Maria Palomba (33)
  2. Andrew Zelenetz (28)
  3. Andrew Intlekofer (27)
  4. Ariela Noy (27)
  5. Paul Hamlin (27)
  6. Steven Horwitz (27)

More People

Years
  1. 2023 (12)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Blood (21)
  2. Blood Advances (3)
  3. Hematological Oncology (3)
  4. Journal of Clinical Oncology (2)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save